News

Filter

Current filters:

Denileukin Diftitox

1 to 9 of 35 results

Japan's Eisai spreads its wings with $325 million acquisition of USA's Morphotek

02-04-2007

In what it describes as a "dramatic leap towards biologic therapeutics," Japan's fourth-largest pharmaceutical…

AlitretinoinAriceptbexaroteneDenileukin DiftitoxdonepezilEisaiOntakPanretinTargretin

Ligand finalizes sale of oncology line to Eisai

06-11-2006

San Diego, USA-based Ligand Pharmaceuticals says it has completed the sale of its oncology product line…

AlitretinoinbexaroteneDenileukin DiftitoxEisaiOntakPanretinTargretin

Japan stock market week to Sept 11, 2006

18-09-2006

Tokyo saw a pullback in the week ended September 11 following see-saw movements. The Nikkei 225 fell…

ActosAlitretinoinbexaroteneBexarotene GelDaiichi SankyoDenileukin DiftitoxEisaiHumulin 70-30Humulin NHumulin RInsulinOntakPanretinPioglitazoneSankyoTargretinTargretin Gel

Ligand's 1st-qtr 2006 revenues up 38%

29-05-2006

USA-based drug developer Ligand Pharmaceuticals says that its first-quarter 2006 losses, which hit $137.1…

Akzo NobelAvinzabexaroteneDenileukin DiftitoxKadianMorphine SulfateMorphine Sulfate Extended-ReleaseOntakOrganonRoxanolTargretin

Ligand buys down Ontak royalties

18-04-2005

The USA's Ligand Pharmaceuticals has exercised the final option under its November 2004 agreement with…

Denileukin DiftitoxLillyOntak

Ligand to buy down Lilly Ontak royalties

17-01-2005

Ligand Pharmaceuticals, which acquired the US rights to the cancer drug Ontak (denileukin diftitox) from…

Denileukin DiftitoxLillyOntak

1 to 9 of 35 results

Back to top